Epigral Reports Q2 Consolidated Net Profit Of ₹65.1 Crore Versus ₹51.2 Crore YoY

Market snapshot: Epigral Limited reported a consolidated net profit of ₹65.1 crore for the second quarter, marking earnings expansion from ₹51.2 crore recorded in the corresponding prior-year period.

Data Snapshot

• Q2 consolidated net profit reached ₹65.1 crore compared to ₹51.2 crore in the corresponding prior-year period.
• Consolidated net profit expanded by ≈27.15% YoY (derived: ₹65.1 crore vs ₹51.2 crore).
• Board approved ₹600 crore investment for entry into Epoxy Resin and Formulations production capacity.

What's Changed

• Q2 consolidated net profit increased to ₹65.1 crore, rising from ₹51.2 crore in the prior-year comparative period.

Key Takeaways

• Epigral demonstrated year-on-year expansion in bottom-line profitability during the quarter.
• Earnings trajectory reflects volume gains and operating stability in specialty chemical segments.

SAHI Perspective

The expansion in net profit to ₹65.1 crore underlines steady execution across Epigral's specialty chemical operations. Continued earnings strength provides fundamental support as the company advances its strategic forward-integration projects.

Market Implications

Year-on-year growth in consolidated net profit supports institutional sentiment toward integrated chemical players with captive raw material security.

Trading Signals

Market Bias: Bullish

Q2 consolidated net profit increased to ₹65.1 crore from ₹51.2 crore YoY (≈27.15% growth), signaling healthy profitability momentum.

Overweight: Specialty Chemicals, Chemical Derivatives

Trigger Factors:

• Sustained capacity utilization in derivative segments
• Stability in key raw material input realizations

Time Horizon: Near-term (0-3 months)

Industry Context

India's specialty chemical sector remains driven by import substitution dynamics and increasing internal value addition in derivative products.

Key Risks to Watch

• Fluctuations in international commodity chemical realizations.
• Potential raw material input price spikes or supply chain disruptions.

Recent Developments

Epigral's board approved entry into the Epoxy Resin and Formulations business with a planned production capacity of 1,25,000 TPA and an estimated capex of ₹600 crore.

Closing Insight

Epigral's quarterly performance reinforces its profit trajectory, supporting its medium-term portfolio transformation into higher-margin derivative products.

High Performance Trading with SAHI.